Prevalence of antibodies against Kaposi's sarcoma associated herpes virus (KSHV) complement inhibitory protein (KCP) in KSHV-related diseases and their correlation with clinical parameters.

• Published in: Vaccine
• Main Authors: Okroj, Marcin, Tedeschi, Rosamaria, Mancuso, Roberta, Brambilla, Lucia, Tourlaki, Athanasia, Dillner, Joakim, Blom, Anna
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier 2011
• Subjects: Other Basic Medicine; Medicinal Chemistry; Microbiology in the medical area; Northern Sweden
• Online Access: https://lup.lub.lu.se/record/1756686; https://doi.org/10.1016/j.vaccine.2010.11.070; https://portal.research.lu.se/files/1688001/1768870.pdf

Kaposi's sarcoma-associated herpes virus (KSHV) encodes its own inhibitor of the complement system, designated KSHV complement control protein (KCP). Previously, we detected anti-KCP antibodies in a small group of 22 patients suffering from Kaposi's sarcoma (KS) and KSHV-related lymphoproliferative diseases (Vaccine, 25:8102-9). Anti-KCP antibodies were more prevalent in individuals suffering from KSHV-related lymphomas than KS and also in those with high titer of antibodies against lytic KSHV antigens. Herein we analyze anti-KCP antibodies in 175 individuals originating from three different groups from northern Sweden or Italy, which included patients suffering from classical or HIV-associated KS, Multicentric Castleman's Disease, KSHV-associated solid lymphoma, pleural effusion lymphoma and healthy individuals with detectable KSHV immune response. Our current study confirmed previous observations concerning antibody prevalence but we also analyzed correlations between anti-KCP antibodies and classical KS evolution, clinical stage and viral load in body fluids. Furthermore, we show that patient's anti-KCP antibodies are able to decrease the ability of KCP to inhibit complement. This fact combined with results of statistical analysis suggests that KCP inactivation by specific antibodies may influence progression of classical KS.